These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 34181497)

  • 1. Healthcare costs of patients with cancer stratified by Khorana score risk levels.
    Khorana AA; Kuderer NM; McCrae K; Milentijevic D; Germain G; Laliberté F; MacKnight SD; Lefebvre P; Lyman GH; Streiff MB
    J Med Econ; 2021; 24(1):866-873. PubMed ID: 34181497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer associated thrombosis and mortality in patients with cancer stratified by khorana score risk levels.
    Khorana AA; Kuderer NM; McCrae K; Milentijevic D; Germain G; Laliberté F; MacKnight SD; Lefebvre P; Lyman GH; Streiff MB
    Cancer Med; 2020 Nov; 9(21):8062-8073. PubMed ID: 32954653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries.
    Lefebvre P; Laliberté F; Nutescu EA; Duh MS; LaMori J; Bookhart BK; Olson WH; Dea K; Schein J; Kaatz S
    J Manag Care Pharm; 2012 Jun; 18(5):363-74. PubMed ID: 22663169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare resource utilization and costs associated with venous thromboembolism in cancer patients treated with anticoagulants.
    Streiff M; Milentijevic D; McCrae KR; Laliberté F; Lejeune D; Lefebvre P; Schein J; Khorana AA
    J Med Econ; 2019 Nov; 22(11):1134-1140. PubMed ID: 31106638
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison between the Khorana prediction score and Caprini risk assessment models for assessing the risk of venous thromboembolism in hospitalized patients with cancer: a retrospective case control study.
    Hu Y; Li X; Zhou H; Lin P; Zhang J; Huang D; Qi M; Tang Y; Yi Q; Liang Z; Wang M
    Interact Cardiovasc Thorac Surg; 2020 Oct; 31(4):454-460. PubMed ID: 32910201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healthcare resource utilization and costs associated with venous thromboembolism recurrence in patients with cancer.
    Khorana AA; McCrae KR; Milentijevic D; Laliberté F; Lejeune D; Crivera C; Lefebvre P
    J Med Econ; 2020 Apr; 23(4):323-329. PubMed ID: 31818164
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population.
    Hlavacek P; Guo JD; Rosenblatt L; Keshishian A; Russ C; Mardekian J; Ferri M; Poretta T; Yuce H; McBane R
    Curr Med Res Opin; 2019 Dec; 35(12):2043-2051. PubMed ID: 31387467
    [No Abstract]   [Full Text] [Related]  

  • 8. Validation of the Khorana Score for Prediction of Venous Thromboembolism After Robot-Assisted Radical Cystectomy.
    Iqbal U; Elsayed AS; Ozair S; Jing Z; James G; Li Q; Hussein AA; Guru KA
    J Endourol; 2021 Jun; 35(6):821-827. PubMed ID: 33218263
    [No Abstract]   [Full Text] [Related]  

  • 9. Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors.
    Lin HM; Pan X; Hou P; Huang H; Wu Y; Ren K; Jahanzeb M
    J Med Econ; 2020 Aug; 23(8):894-901. PubMed ID: 32347754
    [No Abstract]   [Full Text] [Related]  

  • 10. Healthcare costs of NVAF patients treated with rivaroxaban and apixaban in the US.
    Milentijevic D; Germain G; Laliberté F; Bookhart BK; MacKnight SD; Tsang J; Lefebvre P
    J Med Econ; 2020 Nov; 23(11):1365-1374. PubMed ID: 32897766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of the Khorana Score to Assess Venous Thromboembolism and Its Association with Mortality in Cancer Patients: A Retrospective Community-based Observational Experience.
    Ahmed G; Nasir HG; Hall K; Weissmann L
    Cureus; 2020 Apr; 12(4):e7883. PubMed ID: 32489737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting risk of venous thromboembolism in hospitalized cancer patients: Utility of a risk assessment tool.
    Patell R; Rybicki L; McCrae KR; Khorana AA
    Am J Hematol; 2017 Jun; 92(6):501-507. PubMed ID: 28240823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of hospital readmissions for venous thromboembolism and associated hospital costs and length of stay among acute medically ill patients in the US.
    Amin A; Deitelzweig S; Bucior I; Lin J; Lingohr-Smith M; Menges B; Neuman WR
    J Med Econ; 2019 Nov; 22(11):1119-1125. PubMed ID: 31084383
    [No Abstract]   [Full Text] [Related]  

  • 14. Costs of venous thromboembolism associated with hospitalization for medical illness.
    Cohoon KP; Leibson CL; Ransom JE; Ashrani AA; Petterson TM; Long KH; Bailey KR; Heit JA
    Am J Manag Care; 2015 Apr; 21(4):e255-63. PubMed ID: 26244788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world comparison of hospitalization costs for heart failure in type 2 diabetes mellitus patients with established cardiovascular disease treated with canagliflozin versus other antihyperglycemic agents.
    Chen YW; Voelker J; Tunceli O; Pericone CD; Bookhart B; Durkin M
    J Med Econ; 2020 Apr; 23(4):401-406. PubMed ID: 31801393
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase-specific and lifetime economic burden of cervical cancer and endometrial cancer in a commercially insured United States population.
    Shah R; Corman S; Shah A; Kebede N; Nwankwo C
    J Med Econ; 2021; 24(1):1221-1230. PubMed ID: 34686073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population.
    Vekeman F; LaMori JC; Laliberté F; Nutescu E; Duh MS; Bookhart BK; Schein J; Dea K; Olson WH; Lefebvre P
    J Med Econ; 2011; 14(3):324-34. PubMed ID: 21506632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of venous thromboembolism and discriminating capacity of Khorana score in lung cancer patients treated with immune checkpoint inhibitors.
    Alma S; Eloi D; Léa V; Julie C; Valérie M; Pierre G; Hilgers W; Philippe G; Christine Z; Philippe D
    J Thromb Thrombolysis; 2022 Aug; 54(2):287-294. PubMed ID: 35396660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing hypercoagulability and VTE risk using thromboelastography and Khorana score in women with cancers receiving chemotherapy.
    Tera Y; Suh YJ; Fainchtein K; Agrawal A; Mates M; Othman M
    Am J Hematol; 2024 Apr; 99 Suppl 1():S19-S27. PubMed ID: 38425173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare costs associated with rivaroxaban or warfarin use for the treatment of venous thromboembolism.
    Coleman CI; Baugh C; Crivera C; Milentijevic D; Wang SW; Lu L; Nelson WW
    J Med Econ; 2017 Feb; 20(2):200-203. PubMed ID: 27780397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.